Research & Development

Aveo, Novartis scrap $326m antibody licensing deal

US-based Aveo Pharmaceuticals and Swiss drugmaker Novartis have scrapped their $326m worth licensing agreement to develop and commercialize the former’s humanized inhibitory antibody AV-380 and other related antibodies.

TRIGR Therapeutics, ABL Bio collaborate on next generation therapeutic antibodies

TRIGR Therapeutics and ABL Bio have entered into a binding agreement for TRIGR to license the global commercial rights to ABL Bio’s pipeline of novel therapeutic antibodies to treat cancer.

CVC-led consortium to buy majority stake in Recordati for €3.03bn

Private equity firm CVC Capital Partners-led consortium has agreed to acquire controlling stake in Italian drugmaker, Recordati, in a deal valued at €3.03bn.

Broad, Bayer expand partnership to develop therapies for heart failure

The Broad Institute of MIT and Harvard and Bayer are launching the Precision Cardiology Laboratory (PCL), a new endeavor that will pursue scientific insights aimed at developing new therapies for heart failure.

Biogen to pay $700m to increase stake in Samsung Bioepis

Biogen has agreed to increase its stake in biopharmaceutical company Samsung Bioepis to nearly 49.9% in a deal of about $700m with its joint venture (JV) partner Samsung BioLogics.

AbbVie, Calibr partner to develop T-cell therapies for solid tumors

Biopharmaceutical firm AbbVie and Calibr, the drug discovery division of Scripps Research, have entered into a collaboration to develop T-cell therapies aimed mainly at cancer, including solid tumors.

Ionis licenses to Akcea global rights to inotersen in $1.7bn deal

Ionis Pharmaceuticals has licensed to Akcea Therapeutics worldwide rights to inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx, in a transaction potentially worth about $1.7bn.

Recursion Pharmaceuticals uses Splunk machine learning to treat genetic diseases

Biotechnology company Recursion Pharmaceuticals is using Splunk Enterprise and the Splunk Machine Learning Toolkit to reach its target of treating 100 molecular genetic diseases by 2025.

Summit Therapeutics awarded BARDA contract to develop Ridinilazole for CDI

Summit Therapeutics announces that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government's Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, has awarded Summit a contract worth up to $62m.